Skip to main content
Januario Castro, MD, Oncology, Phoenix, AZ, Mayo Clinic Hospital

JanuarioECastroMD

Oncology Phoenix, AZ

Hematologic Oncology

Professor of Medicine

Dr. Castro is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Castro's full profile

Already have an account?

Education & Training

  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2000
  • Industrial University of Santander Faculty of Medicine
    Industrial University of Santander Faculty of MedicineClass of 1992, MD
  • Colegio La Salle
    Colegio La SalleB.Sc., 1979 - 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2000 - 2026
  • AZ State Medical License
    AZ State Medical License 2018 - 2024
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Research Award Gateway Foundation, 2008
  • Investigator Award CLL Global Research foundation, 2005
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase ½ study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia  
    Byrd JC, Kipps TJ, Flinn IW, Castro JE, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S, Blood, 1/1/2010
  • Development of allogeneic hematopoietic stem cell transplantation (HSCT) (Chapter Review)  
    Castro JE, Ball ED, Cancer Treat Res, 1/1/2002
  • Nesidioblastosis: Report of the fist adult cases in Colombia  
    Castro JE, Delgado JC, Landazabal G, Rev Col Cirugia, 1/1/1994
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

  • Clinical Review various topics in Hematology and Oncology. 
    Castro JE, PDxMED - Online Medical Review, Elsevier Science
    http://www.firstconsult.com
    London, UK - 1/1/2004

Press Mentions

  • Behind the Scenes–Mayo Clinic Research
    Behind the Scenes–Mayo Clinic ResearchSeptember 12th, 2019

Grant Support

  • Clinical Trial: Adenovirus Cd-154 In Subjects With CLLNational Center For Research Resources2010
  • Clinical Trial: A Phase II Study Of Repeat Intranodal Injections Of Adenovirus-CNational Center For Research Resources2010
  • Phase I, Open-Label Dose-EscalationFood And Drug Administration2008–2010
  • Clinical Trial: PK Study Of Intranodal Injection Of Adenovirus-Cd154 In PatientsNational Center For Research Resources2008–2009
  • Immunotherapy For Chronic Lymphocytic LeukemiaNational Cancer Institute2004–2008

Other Languages

  • Spanish

Hospital Affiliations